TP53/p53 as a prognostic factor

Prognostic and Predictive Factors in Gynecologic Cancers

Volumn , Issue , 2007, Pages 45-62

  Rose, Stephen L ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85026262230     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (70)

1. Anderson MJ, Stanbridge EJ. Tumor suppressor genes studied by cell hybridization and chromosome transfer. FASEB J 1993; 7: 826-33.
2. Knudson AG, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci USA 1975; 72: 5116-20.
3. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1: 157-70.
4. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature 1997; 386: 761-3.
5. Harvey M, McArthur MJ, Montgomery CJ, et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 1993; 5: 225-9.
6. Lu X. p53: a heavily dictated dictator of life and death. Curr Opin Genet Dev 2005; 15: 27-33.
7. Israels ED, Israels LG. The cell cycle. Oncologist 2000; 5: 510-13.
8. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252: 1708.
9. Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998; 391: 597-601.
10. Schneider E, Montenarh M, Wagner P. Regulation of CAK kinase activity by p53. Oncogene 1998; 17: 2733-41.
11. 1-S progression by the p53- inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol 2000; 20: 1797-815.
12. Flatt PM, Tang LJ, Scatena CD. p53 regulation of G2 checkpoint is retinoblastoma protein dependent. Mol Cell Biol 2000; 20: 4210-23.
13. Jin S, Antinore MJ, Lung FD. The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. J Biol Chem 2000; 275: 16602-8.
14. Zhan Q, Antinore MJ, Wang XW. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 1999; 18: 2892-900.
15. Hermeking H, Lengauer C, Polyak K. 14-3-3-σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.
16. Peng CY, Graves PR, Thomas RS. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277: 1501-5.
17. Ferrell JE. How regulated protein translocation can produce switch-like responses. Trends Biochem Sci 1998; 23: 461-5.
18. Chan TA, Hermeking H, Lengauer C. 14-3-3-σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 616-20.
19. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005; 331: 851-8.
20. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003; 116: 4077-85.
21. Schuler M, Bossy-Wetzel E, Godstein JC, et al. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. Biol Chem 2000; 275: 7337-42.
22. MacLachlan TK, El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci USA 2002; 99: 9492-7.
23. Iyer NG, Chin S, Ozdag H, et al. p300 regulates p53 dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci USA 2004; 101: 7386-91.
24. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev 2003; 3: 401-10.
25. Holmgren L, Jackson G, Arbiser J. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 1998; 17: 819-24.
26. Gautam A, Densmore CL, Melton S, et al. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002; 9: 28-36.
27. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725.
28. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991; 253: 49.
29. Skilling JS, Sood AK, Niemann T, et al. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996; 13: 117-23.
30. Okamoto A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991; 51: 5171-6.
31. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 90: 4961-5.
32. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993; 85: 1513-19.
33. Wertheim I, Muto MG, Welsh WR, et al. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994; 86: 1549-51.
34. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000; 89: 2006-17.
35. Okuda T, Otsuka J, Sekizawa A, et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol 2003; 88: 318-25.
36. Ho ES, Lai C, Hsich Y, Chen J. p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 2001; 80: 189-93.
37. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979-84.
38. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64-9.
39. Sheridan E, Silcocks P, Smith J, et al. p53 mutation in a series of epithelial ovarian cancers from the UK, and its prognostic significance. Eur J Cancer 1994: 1701-4.
40. Van der Zee AGJ, Hollema H, Suurmeijer AJH, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factores in ovarian carcinomas. J Clin Oncol 1995; 13: 70-8.
41. Allan LA, Campbell MK, Milner BJ, et al. The significance of p53 mutation and over-expression in ovarian cancer prognosis. Int J Gynecol Cancer 1996; 6: 483-90.
42. Geisler JP, Geisler HE, Wiemann MC, et al. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 1997; 66: 435-8.
43. Goff BA, Ries JA, Els LP, et al. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol 1998; 70: 378-85.
44. Marx D, Meden H, Ziemek T, et al. Expression of the p53 tumor suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer 1998; 34: 845-50.
45. Mano Y, Kikuchi Y, Yamamoto K, et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 1999; 35: 1214-19.
46. Ferrandina G, Fagotti A, Salerno MG, et al. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 1999; 81: 733-40.
47. Baekelandt M, Kristensen GB, Nesland JM, et al. Clinical significance of apoptosis-related factors p53, mdm2, and bcl-2 in advanced ovarian cancer. J Clin Oncol 1999; 17: 2061-8.
48. Sagarra R, Andrade L, Martinez E, et al. p53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer. Int J Gynecol Cancer 2002; 12: 720-7.
49. Tachibana M, Watanabe J, Matsushima Y, et al. Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: a multivariate analysis of expression of p53, retinoblastoma, and related proteins. Int J Gynecol Cancer 2003; 13: 598-606.
50. Nielsen JS, Jakobsen E, Holund B, et al. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14: 1086-96.
51. Hashiguchi Y, Tsuda H, Inoue T, et al. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 2004; 35: 165-75.
52. Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004; 10: 5168-77.
53. Dogan E, Saygili U, Tuna B, et al. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol 2005; 97: 46-52.
54. Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984-97.
55. Smith-Sorensen B, Kaern J, Holm R, et al. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to p53 gene status. Br J Cancer 1998; 78: 375-81.
56. Fallows S, Price J, Atkinson RJ, et al. p53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001; 19: 68-75.
57. Schuyer M, van der Burg MEL, Henzen-Logmans SC, et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 2001; 85: 1359-67.
58. Niwa K, Itoh M, Murase T, et al. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 1994; 70: 1191-7.
59. Havrilesky L, Darcy KM, Hamdan H, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3814-25.
60. Rose SL, Robertson AD, Goodheart MJ, et al. The impact of p53 protein core domain structural alteration in ovarian cancer survival. Clin Cancer Res 2003; 9: 4139-44.
61. Wang Y, Helland A, Holm R, et al. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer 2004; 90: 678-85.
62. Leitao MM, Boyd J, Hummer A, et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 2004; 28: 147-59.
63. Wang Y, Kringen P, Kristensen GB, et al. Effect of the codon 72 polymorphism (c.215G>C, p. Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 2004; 24: 21-34.
64. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-14.
65. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996; 18: 1617.
66. Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-66.
67. Kim CK, Choi EJ, Choi SH, et al. Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC. Gynecol Oncol 2003; 90: 265-72.
68. Takimoto R, Wang W, Dicker DT, et al. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002; 1: 47-55.
69. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-28.
70. Bykov VJ, Issaeva N, Selivanova G, et al. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute Database. Carcinogenesis 2002; 23: 2011-18.